Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Human Insulin Market 2018-2024 - Key Players are Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca - ResearchAndMarkets.com

Research and Markets
Posted on: 08 Mar 18

The "Global Human Insulin Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

The Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 2017-2023

The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin.

Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market.

Lantus is the major insulin drug in the market. Due to the loss of patents, the drug has got competition in the form of biosimilar by name Basaglar from Eli Lilly. After the loss of share for its biosimilar counterpart, the drug lost its value for its follow-up drug Toujeo. Since the launch of Toujeo in April 2015, the company has been switching over as many patients as possible to the newer drug to fill the sales gap caused by the reduced revenue of Lantus.

Key Players:

Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market.

The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.

Key Topics Covered:

1. Industry Outlook

2. Report Outline

3. Market Snapshot

4. Market Outline

5. Market Characteristics

6. Insulin Types: Market Size and Analysis

7. Types: Market Size and Analysis

8. Regions: Market Size and Analysis

9. Competitive Landscape

10. Vendor Profiles

11. Companies to Watch For

For more information about this report visit https://www.researchandmarkets.com/research/rq54pl/global_human?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180308005511/en/

Business Wire
www.businesswire.com

Last updated on: 08/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.